JAGX News & Events

Jaguar Health family company Napo Pharmaceuticals announced that, based on the FDA support for Napo's protocol amendment for its clinical trial to evaluate the safety and efficacy of its novel crofelemer powder-for-oral-solution formulation in pediatric patients with intestinal failure due to MVID, an ultrarare pediatric disorder, Napo plans to initiate a single-blind extension phase for the trial. The extended treatment period has the potential to improve clinical benefit of crofelemer through reduction of parenteral support requirements, which may result in disease progression-modification of MVID. The dose selection for the single-blind extension phase will be determined by the study's independent Data Monitoring Committee, which will ensure that the study clinicians and Napo personnel will remain blinded. Currently, approximately 30% of the participating MVID patients have completed the study's double-blind treatment phase and the clinical investigators are supporting the patients' participation in the single-blind extended phase.

Jaguar Health announced that Magdalena Biosciences, a US-based joint venture formed by Jaguar and Canada-based Filament Health Corp., has initiated a preclinical study evaluating the effectiveness of a whole leaf coca extract for appetite suppression. The coca leaf extract is Magdalena's drug candidate for post-GLP-1 weight loss management. This one-month study in mice is being conducted in Alberta, Canada. The coca leaf that is part of this Magdalena research and development program was provided to Magdalena by Empresa Nacional de La Coca, a Peruvian state company dedicated to the commercialization of the coca leaf and derivatives, with an Internationally Recognized Certificate of Compliance in compliance with the Nagoya Protocol requirements of Peru. As announced, Magdalena also plans to evaluate a variety of potential mental health and central nervous system indications for coca, including attention-deficit/hyperactivity disorder and other neuropsychiatric indications.

Jaguar Health announced that the Company has strengthened its balance sheet by restructuring and reducing its royalty obligations and debt held by affiliates of Chicago Venture Partners L.P., including the extinguishment of 48,212 warrants. The restructuring consisted of an initial reduction of approximately 10% of royalty obligations and debt; extending the maturity date by three years for a secured revolving line of credit for approximately $7 million put in place in November 2025; and ensuring that there are no maturity dates before July 2026 for any debt held by affiliates of Chicago Venture Partners L.P.